FDA Approves Liquid Formulation of Seizure Medication
Eprontia is the first liquid formulation of topiramate approved to both treat and prevent seizure.
The FDA has approved Azurity Pharmaceuticals’ Eprontia (topiramate), an oral solution that is used as a monotherapy and as adjunctive therapy for patients two years of age and older with partial-onset or primary tonic-clonic seizure, as well as to prevent seizures. Eprontia 25 mg/mL is a ready-to-use liquid medication for those who have trouble swallowing pills.
Michael C. Smith, M.D.
“Clinical challenges have existed for years for clinicians looking for a high quality, predictable formulation option of topiramate to effectively meet the varied needs of patients and caregivers,” Michael C. Smith, M.D., said in a statement. Smith is director of Rush Epilepsy Center and professor in the Department of Neurological Sciences at Rush University Medical Center.
Azurity acquired Eprontia and two other neurology products, lamotrigine and zonisamide, from Eton Pharmaceuticals in February 2021. Eton developed the products, which are liquid formulations, to treat seizure. Both are under review at the FDA.
Azurity will be responsible for commercialization. Eton will receive a $5 million milestone payment upon launch of Eprontia, a royalty on net sales, and potential commercial milestones.
Globally, an estimated 65 million people have epilepsy, and 1 billion suffer from migraine. In the United States, one in 26 people will develop epilepsy at some point during their lifetime and about 39 million people suffer from migraine.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 24th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 22nd 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More
